


SmartBreast Corp Revenue
Medical Equipment Manufacturing • Los Angeles, California, United States • 1-10 Employees
SmartBreast Corp revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $1,400,000 |
| Total funding | No funding |
Key Contact at SmartBreast Corp
Eduardo A. Santos
Co-Founder & Vice President
Company overview
| Headquarters | 14930 Ventura Blvd, Sherman Oaks (Los Angeles), California 91403, US |
| Phone number | +17245843266 |
| Website | |
| NAICS | 3391 |
| Keywords | MBI, Breast Cancer, Breast Screening, Breast Cancer Detection, Breast Cancer Diagnosis, Dense Breasts, Molecular Breast Imaging |
| Founded | 2019 |
| Employees | 1-10 |
| Socials |
SmartBreast Corp Email Formats
SmartBreast Corp uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@smartbreast.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@smartbreast.com | 100% |
About SmartBreast Corp
SmartBreast empowers women with dense breasts to defeat cancer through early detection and treatment. 1 of every 2 Western women (2 of every 3 Asian women) have dense breasts, which is a normal condition. Until recently, most women were never told about their breast density and the facts that 1) dense breasts increase the risk for cancer up to 5 times and 2) screening mammography fails 70% of the time in dense breasts! Because dense tissue and cancer are both white on X-ray mammograms, cancer can easily be hidden until it is large and late-stage, when treatment is severe (mastectomy, radiation, chemotherapy, 29% survival after 5 years). When breast cancer is found early, survival is 99% after 5 years - the cancer is cured! SmartBreast offers one of the best methods to find early-stage cancer in dense breasts, called "Molecular Breast Imaging" or simply "MBI." MBI uses 3 innovations to solve the dense-breast problem: 1) MBI uses a tracer molecule (Nobel prize discovery) that concentrates in tumor cells, 2) MBI uses gamma photons that safely pass through dense breast tissue, and 3) MBI uses specially designed solid-state gamma cameras (based on another Nobel prize) to image the tracer concentrations in the breast. There is a bonus benefit to MBI: unlike mammography, MBI is painless, only mildly immobilizing the breast. We analyzed 24 publications (meta-analysis) to discover that the Cancer Detection Rate (CDR) for Digital Mammography (DM) is 4 cancers for every 1,000 dense-breast women screened. Digital Breast Tomosynthesis (DBT or 3D DM) finds 5 cancers; ultrasound (U/S) finds 7. Three modalities (MBI, Contrast-Enhanced Mammography (CEM), and MRI) each find 14 cancers. This means that DM misses 10 (71%), DBT misses 9 (61%) and U/S misses 7 (49%)! MBI is FDA-cleared and reimbursed in most locations, including 12 countries. SmartBreast manufactures, sells, installs, and services MBI. Write to info@smartbreast.com for more information.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
SmartBreast Corp has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
SmartBreast Corp has never raised funding before.
SmartBreast Corp Tech Stack
Discover the technologies and tools that power SmartBreast Corp's digital infrastructure, from frameworks to analytics platforms.
Security
Page builders
Form builders
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Programming languages
Blogs
Analytics
Video players
UI frameworks
Frequently asked questions
4.8
40,000 users



